GW182 Antibody

Western Blot: GW182 Antibody [NBP1-28751] -

Western Blot: GW182 Antibody [NBP1-28751] - TNRC6A interacts with eIF4E2. (A) Plasmids expressing proteins indicated were transfected into HEK293T cells. At 48 h posttransfection, cells were lysed & the lysates were immunoprecipitated (IP) in the presence of RNase A. The precipitates were resolved on SDS-PAGE followed by Western blotting. (B) A plasmid expressing Flag-tagged eIF4E1 or eIF4E2 was transfected into HEK293T cells. At 48 h posttransfection, cells were lysed & the lysates were immunoprecipitated with the anti-TNRC6A antibody or control IgG in the presence of RNase A. The precipitates were resolved on SDS-PAGE followed by Western blotting. (C) Upper: schematic representation of TNRC6A truncation mutants. Lower: A plasmid expressing the TNRC6A mutant indicated & a plasmid expressing myc-tagged eIF4E2 were transiently transfected into HEK293T cells. At 48 h posttransfection, cells were lysed & the lysates were immunoprecipitated with anti-Flag antibody in the presence of RNase A followed by Western blotting. (D) Bacterially expressed Flag-tagged eIF4E2 or eIF4E1 was incubated with Glutathione Sepharose 4B bound fusion protein of GST & the C-terminal domain of TNRC6A (6A-C). The precipitates were washed & resolved on SDS-PAGE followed by commassie brilliant blue staining (lower) & Western blotting (upper) Image collected & cropped by CiteAb from the following publication (https://academic.oup.com/proteincell/article/8/10/750/6765124), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GW182 Antibody [NBP1-28751] -

Western Blot: GW182 Antibody [NBP1-28751] - Cellular expression of TBG nanocapsule uptake & RNAi-CK2 oligomer processing markers in xenograft tumors(A) Expression levels for key nanocapsule entry & oligomer processing proteins were detected by immunoblot in PC3-LN4 & 22Rv1 cytosolic tumor lysates from the dose response studies. The signals for four mice per group are shown, the proteins detected are indicated on the right, & the size markers are indicated on the left. Two exposures are provided for GW182 in order to show detectable signals in linear range in all lanes for both PC3-LN4 & 22Rv1 tumor lysates. T1, T2, T3, & T4 labels indicate different tumors within the treatment & xenograft model groups. Antibody sourcing information is listed in Materials & Methods. Actin signal was used as the loading control. (B) Indirect immunofluorescence detection of GW182 proteins & GW bodies in PC3-LN4 tumors. Results from 3 mice treated with TNG-RNAi-CK2 & 3 mice treated with TBG-RNAi-F7 are shown. T1, T2, & T3 labels indicate different tumors. Antibody sourcing information is listed in Materials & Methods. Nuclei were counterstained with Sytox® Green. Scale bar represents 20 μm. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.11442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GW182 Antibody [NBP1-28751] -

Western Blot: GW182 Antibody [NBP1-28751] - TNRC6A interacts with eIF4E2. (A) Plasmids expressing proteins indicated were transfected into HEK293T cells. At 48 h posttransfection, cells were lysed & the lysates were immunoprecipitated (IP) in the presence of RNase A. The precipitates were resolved on SDS-PAGE followed by Western blotting. (B) A plasmid expressing Flag-tagged eIF4E1 or eIF4E2 was transfected into HEK293T cells. At 48 h posttransfection, cells were lysed & the lysates were immunoprecipitated with the anti-TNRC6A antibody or control IgG in the presence of RNase A. The precipitates were resolved on SDS-PAGE followed by Western blotting. (C) Upper: schematic representation of TNRC6A truncation mutants. Lower: A plasmid expressing the TNRC6A mutant indicated & a plasmid expressing myc-tagged eIF4E2 were transiently transfected into HEK293T cells. At 48 h posttransfection, cells were lysed & the lysates were immunoprecipitated with anti-Flag antibody in the presence of RNase A followed by Western blotting. (D) Bacterially expressed Flag-tagged eIF4E2 or eIF4E1 was incubated with Glutathione Sepharose 4B bound fusion protein of GST & the C-terminal domain of TNRC6A (6A-C). The precipitates were washed & resolved on SDS-PAGE followed by commassie brilliant blue staining (lower) & Western blotting (upper) Image collected & cropped by CiteAb from the following publication (https://academic.oup.com/proteincell/article/8/10/750/6765124), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GW182 Antibody [NBP1-28751] -

Western Blot: GW182 Antibody [NBP1-28751] - Downregulation of eIF4E2 increases the protein levels of endogenous IMP1. HeLa cells were transfected with siRNAs indicated. At 48 h posttransfection, cells were lysed. (A) A fraction of the lysate was subjected to SDS-PAGE followed by Western blotting. (B) The rest cell lysate was used to extract RNA, followed by RT-qPCR measurement of the RNA levels. Relative IMP1 protein levels were quantified with the Image J software & normalized with the beta-actin levels. Translational efficiency was calculated as relative protein level divided by mRNA level. Fold repression was calculated as the value in the presence of the control siRNA divided by that in the presence of the targeting siRNA. Data presented are means ± SD of three independent experiments. The P value is determined by two-tailed Student’s t test. ns, nonsignificant. *P < 0.05; **P < 0.01; ***P < 0.005. Ctrli, control siRNA; TNi, siRNAs targeting TNRC6A & TNRC6B; 4E2i, siRNA targeting eIF4E2; 4Ei, siRNA targeting eIF4E1 Image collected & cropped by CiteAb from the following publication (https://academic.oup.com/proteincell/article/8/10/750/6765124), licensed under a CC-BY license. Not internally tested by Novus Biologicals.